Skip to main content

Animations

MJFF Publications

5161 - 5170 of 6324 Results
Title
Year
  • Year
  • 2019
  • 2018
  • 2017
  • 2020
  • 2017
  • 2019
  • 2024
  • 2024
  • 2021
  • 2014
  • Summary Details
    OPEN
    Title: Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1073/pnas.1814909116
    Citation Count: 98
  • Summary Details
    OPEN
    Title: α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons
    Journal Name: Acta Neuropathologica Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s40478-018-0537-x
    Citation Count: 83
  • Summary Details
    OPEN
    Title: Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.aam9080
    Citation Count: 736
  • Summary Details
    OPEN
    Title: MicroRNA Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28143
    Citation Count: 16
  • Summary Details
    OPEN
    Title: O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson’s disease
    Journal Name: Molecular Brain
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13041-017-0311-1
    Citation Count: 81
  • Summary Details
    OPEN
    Title: Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30140-1
    Citation Count: 88
  • Summary Details
    OPEN
    Title: The Amplification of Alpha‐Synuclein Amyloid Fibrils is Suppressed under Fully Quiescent Conditions
    Journal Name: Angewandte Chemie International Edition
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/anie.202419173
    Citation Count: 3
  • Summary Details
    OPEN
    Title: CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein
    Journal Name: Journal of Chemical Information and Modeling
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jcim.4c01267
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Interplay between tau and α‐synuclein liquid–liquid phase separation
    Journal Name: Protein Science
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/pro.4025
    Citation Count: 83
  • Summary Details
    OPEN
    Title: MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a
    Journal Name: Journal of Neuroimmunology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jneuroim.2014.11.004
    Citation Count: 64
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.